Cargando…
Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential
In 2010, all young patients treated for intrathoracic Hodgkin lymphoma (HL) at one of 10 radiotherapy centers in the province of Quebec received 3D conformal photon therapy. These patients may now be at risk for late effects of their treatment, notably secondary malignancies and cardiac toxicity. We...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690189/ https://www.ncbi.nlm.nih.gov/pubmed/26699298 http://dx.doi.org/10.1120/jacmp.v16i5.5386 |
_version_ | 1783279551568150528 |
---|---|
author | Toltz, Allison Shin, Naomi Mitrou, Ellis Laude, Cecile Freeman, Carolyn R. Seuntjens, Jan Parker, William Roberge, David |
author_facet | Toltz, Allison Shin, Naomi Mitrou, Ellis Laude, Cecile Freeman, Carolyn R. Seuntjens, Jan Parker, William Roberge, David |
author_sort | Toltz, Allison |
collection | PubMed |
description | In 2010, all young patients treated for intrathoracic Hodgkin lymphoma (HL) at one of 10 radiotherapy centers in the province of Quebec received 3D conformal photon therapy. These patients may now be at risk for late effects of their treatment, notably secondary malignancies and cardiac toxicity. We hypothesized that more complex radiotherapy, including intensity‐modulated proton therapy (IMPT) and possibly IMRT (in the form of helical tomotherapy (HT)), could benefit these patients. With institutional review board approval at 10 institutions, all treatment plans for patients under the age of 30 treated for HL during a six‐month consecutive period of 2010 were retrieved. Twenty‐six patients were identified, and after excluding patients with extrathoracic radiation or treatment of recurrence, 20 patients were replanned for HT and IMPT. Neutron dose for IMPT plans was estimated from published measurements. The relative seriality model was used to predict excess risk of cardiac mortality. A modified linear quadratic model was used to predict the excess absolute risk for induction of lung cancer and, in female patients, breast cancer. Model parameters were derived from published data. Predicted risk for cardiac mortality was similar among the three treatment techniques (absolute excess risk of cardiac mortality was not reduced for HT or IMPT ([Formula: see text]) as compared to 3D CRT). Predicted risks were increased for HT and reduced for IMPT for secondary lung cancer ([Formula: see text]) and breast cancers ([Formula: see text]) as compared to 3D CRT. PACS numbers: 87.55.dh, 87.55.dk |
format | Online Article Text |
id | pubmed-5690189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56901892018-04-02 Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential Toltz, Allison Shin, Naomi Mitrou, Ellis Laude, Cecile Freeman, Carolyn R. Seuntjens, Jan Parker, William Roberge, David J Appl Clin Med Phys Radiation Oncology Physics In 2010, all young patients treated for intrathoracic Hodgkin lymphoma (HL) at one of 10 radiotherapy centers in the province of Quebec received 3D conformal photon therapy. These patients may now be at risk for late effects of their treatment, notably secondary malignancies and cardiac toxicity. We hypothesized that more complex radiotherapy, including intensity‐modulated proton therapy (IMPT) and possibly IMRT (in the form of helical tomotherapy (HT)), could benefit these patients. With institutional review board approval at 10 institutions, all treatment plans for patients under the age of 30 treated for HL during a six‐month consecutive period of 2010 were retrieved. Twenty‐six patients were identified, and after excluding patients with extrathoracic radiation or treatment of recurrence, 20 patients were replanned for HT and IMPT. Neutron dose for IMPT plans was estimated from published measurements. The relative seriality model was used to predict excess risk of cardiac mortality. A modified linear quadratic model was used to predict the excess absolute risk for induction of lung cancer and, in female patients, breast cancer. Model parameters were derived from published data. Predicted risk for cardiac mortality was similar among the three treatment techniques (absolute excess risk of cardiac mortality was not reduced for HT or IMPT ([Formula: see text]) as compared to 3D CRT). Predicted risks were increased for HT and reduced for IMPT for secondary lung cancer ([Formula: see text]) and breast cancers ([Formula: see text]) as compared to 3D CRT. PACS numbers: 87.55.dh, 87.55.dk John Wiley and Sons Inc. 2015-09-08 /pmc/articles/PMC5690189/ /pubmed/26699298 http://dx.doi.org/10.1120/jacmp.v16i5.5386 Text en © 2015 The Authors. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Radiation Oncology Physics Toltz, Allison Shin, Naomi Mitrou, Ellis Laude, Cecile Freeman, Carolyn R. Seuntjens, Jan Parker, William Roberge, David Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential |
title | Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential |
title_full | Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential |
title_fullStr | Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential |
title_full_unstemmed | Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential |
title_short | Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential |
title_sort | late radiation toxicity in hodgkin lymphoma patients: proton therapy's potential |
topic | Radiation Oncology Physics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690189/ https://www.ncbi.nlm.nih.gov/pubmed/26699298 http://dx.doi.org/10.1120/jacmp.v16i5.5386 |
work_keys_str_mv | AT toltzallison lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential AT shinnaomi lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential AT mitrouellis lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential AT laudececile lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential AT freemancarolynr lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential AT seuntjensjan lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential AT parkerwilliam lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential AT robergedavid lateradiationtoxicityinhodgkinlymphomapatientsprotontherapyspotential |